Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in patients with moderate to severe hypertension.

Next Previous
Search
Trial Profile

An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in patients with moderate to severe hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Amlodipine
  • Indications Hypertension
  • Focus Biomarker; Registrational; Therapeutic Use

    • Most Recent Events

    • 01 Sep 2012 Primary endpoint mean seated systolic blood pressure has been met according to results published in the International Journal of Clinical Practice.
    • 01 Sep 2012 Results published in the International Journal of Clinical Practice.
    • 27 Aug 2010 FDA approval of Tekamlo was based on clinical trial data involving more than 5000 patients, including data from this study, according to a Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top